B2M/CIITA Double Knockout THP-1 Cell Line

Description

B2M/CIITA Double Knockout THP-1 Cell Line is generated from the human monocytic THP-1 cell line using CRISPR/Cas9-mediated gene editing to disrupt both Beta-2-microglobulin (B2M) and Class II Major Histocompatibility Complex Transactivator (CIITA) genes. This dual knockout model exhibits loss of MHC class I (due to B2M knockout) and MHC class II (due to CIITA knockout) expression, making it an ideal tool for studying immune evasion, allogeneic cell therapies, and graft rejection mechanisms. THP-1 cells grow in suspension with round morphology and are widely used in macrophage differentiation, antigen presentation, and immunotherapy research. The edited cells are maintained at low passage numbers (<P20) to ensure genetic stability, with knockout efficiency validated through PCR, sequencing, or Western blot. The cell line undergoes rigorous quality control and is confirmed free of contamination from HIV-1, HBV, HCV, Syphilis, mycoplasma, fungi, yeast, and bacteria.